Methadone showed no clear difference in use of substance compared with oral slow‐release morphine (low certainty).
It is very uncertain whether hyaluronic acid‐selected sperm (HA‐ICSI) changes live birth per woman randomly assigned compared with viscous medium containing HA (SpermSlow) (very low certainty).
It is very uncertain whether hyaluronic acid‐selected sperm (HA‐ICSI) changes miscarriage per woman randomly assigned compared with viscous medium containing HA (SpermSlow) (very low certainty).
It is very uncertain whether hyaluronic acid‐selected sperm (HA‐ICSI) changes miscarriage per clinical pregnancy compared with viscous medium containing HA (SpermSlow) (very low certainty).
It is very uncertain whether hyaluronic acid‐selected sperm (HA‐ICSI) changes clinical pregnancy per woman randomly assigned compared with viscous medium containing HA (SpermSlow) (very low certainty).
It is very uncertain whether rapid changes completion of withdrawal treatment − Outpatient compared with slow taper of buprenorphine dose (very low certainty).
Rapid showed no clear difference in number abstinent at completion of dose taper − Inpatient compared with slow taper of buprenorphine dose (low certainty).
It is very uncertain whether rapid changes number abstinent at completion of dose taper − Outpatient compared with slow taper of buprenorphine dose (very low certainty).
Rapid showed no clear difference in completion of withdrawal treatment − Inpatient compared with slow taper of buprenorphine dose (low certainty).
Fast absorbable showed no clear difference in incisional hernia compared with slow absorbable sutures (moderate certainty).
Fast absorbable showed no clear difference in wound infection at last compared with slow absorbable sutures (moderate certainty).
Fast absorbable showed no clear difference in wound dehiscence at last compared with slow absorbable sutures (moderate certainty).
It is very uncertain whether fast absorbable changes sinus or fistula formation at last compared with slow absorbable sutures (very low certainty).
Antioxidant multivitamin and mineral supplement probably leads to lower progression to late AMD (neovascular AMD, geographic atrophy, or both) compared with placebo or no treatment (moderate certainty).
Lutein with or without zeaxanthin showed no clear difference in progression to geographic atrophy compared with placebo (low certainty).
Lutein with or without zeaxanthin showed no clear difference in progression to visual loss (loss of 3 or more lines on logMAR chart) compared with placebo (low certainty).
It is very uncertain whether lutein with or without zeaxanthin changes adverse effects compared with placebo (very low certainty).
The review found no eligible studies for this question.